ArticleOncotarget2020

Successful administration of sequential TVEC and pembrolizumab followed by Temozolomide in immunotherapy refractory intracranial metastatic melanoma with acquired B2M mutation.

Karam Khaddour et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.